203 related articles for article (PubMed ID: 15062167)
1. Is an 192Ir permanent seed implant feasible for prostate brachytherapy?
Glasgow GP; Dogan N; Mohideen N
Brachytherapy; 2002; 1(4):195-203. PubMed ID: 15062167
[TBL] [Abstract][Full Text] [Related]
2. Can the cost of permanent prostate implants be reduced? An argument for peripheral loading with higher strength seeds.
Maguire PD; Waterman FM; Dicker AP
Tech Urol; 2000 Jun; 6(2):85-8. PubMed ID: 10798805
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of high- and low-source strength (125)I prostate seed implants.
Narayana V; Troyer S; Evans V; Winfield RJ; Roberson PL; McLaughlin PW
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):44-51. PubMed ID: 15629592
[TBL] [Abstract][Full Text] [Related]
4. Radiation exposure after permanent prostate brachytherapy.
Cattani F; Vavassori A; Polo A; Rondi E; Cambria R; Orecchia R; Tosi G
Radiother Oncol; 2006 Apr; 79(1):65-9. PubMed ID: 16564593
[TBL] [Abstract][Full Text] [Related]
5. Radiation safety aspects of brachytherapy for prostate cancer using permanently implanted sources. A report of ICRP Publication 98.
International Commission on Radiological Protection
Ann ICRP; 2005; 35(3):iii-vi, 3-50. PubMed ID: 16330284
[TBL] [Abstract][Full Text] [Related]
6. A study of a pretreatment method to predict the number of I-125 seeds required for prostate brachytherapy.
Al-Qaisieh B; Brearley E; St Clair S; Flynn A
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):304-7. PubMed ID: 16618585
[TBL] [Abstract][Full Text] [Related]
7. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era?
Kudchadker RJ; Swanson DA; Kuban DA; Lee AK; Bruno TL; Frank SJ
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):623-7. PubMed ID: 18410998
[TBL] [Abstract][Full Text] [Related]
8. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
Nickers P; Thissen B; Jansen N; Deneufbourg JM
Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
[TBL] [Abstract][Full Text] [Related]
9. Dosimetry accuracy as a function of seed localization uncertainty in permanent prostate brachytherapy: increased seed number correlates with less variability in prostate dosimetry.
Su Y; Davis BJ; Furutani KM; Herman MG; Robb RA
Phys Med Biol; 2007 Jun; 52(11):3105-19. PubMed ID: 17505092
[TBL] [Abstract][Full Text] [Related]
10. The robustness of dose distributions to displacement and migration of 125I permanent seed implants over a wide range of seed number, activity, and designs.
Beaulieu L; Archambault L; Aubin S; Oral E; Taschereau R; Pouliot J
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1298-308. PubMed ID: 15001275
[TBL] [Abstract][Full Text] [Related]
11. Effect of random seed placement error in permanent transperineal prostate seed implant.
Bues M; Holupka EJ; Meskell P; Kaplan ID
Radiother Oncol; 2006 Apr; 79(1):70-4. PubMed ID: 16515813
[TBL] [Abstract][Full Text] [Related]
12. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy.
Wust P; von Borczyskowski DW; Henkel T; Rosner C; Graf R; Tilly W; Budach V; Felix R; Kahmann F
Radiother Oncol; 2004 Oct; 73(1):39-48. PubMed ID: 15465144
[TBL] [Abstract][Full Text] [Related]
13. The effect of the radial function on I-125 seeds used for permanent prostate implantation.
Pickett B; Pouliot J
Med Dosim; 2004; 29(3):204-9. PubMed ID: 15324917
[TBL] [Abstract][Full Text] [Related]
14. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
15. Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk.
Crook JM; Potters L; Stock RG; Zelefsky MJ
Brachytherapy; 2005; 4(3):186-94. PubMed ID: 16182218
[TBL] [Abstract][Full Text] [Related]
16. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy.
Raben A; Rusthoven KE; Sarkar A; Glick A; Benge B; Jacobs D; Raben D
Brachytherapy; 2009; 8(3):297-303. PubMed ID: 19213608
[TBL] [Abstract][Full Text] [Related]
17. [Advances in brachytherapy--focusing on the permanent implant for early prostate carcinoma].
Hirokawa Y
Gan To Kagaku Ryoho; 2003 Dec; 30(13):2056-61. PubMed ID: 14712765
[TBL] [Abstract][Full Text] [Related]
18. Improvement of transperineal implant dosimetry by intraoperative cystoscopic confirmation of prostate anatomy.
Baird MC; Holt RW; Selby TL
J Urol; 2000 Aug; 164(2):406-10. PubMed ID: 10893597
[TBL] [Abstract][Full Text] [Related]
19. Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis.
Merrick GS; Butler WM; Wallner KE; Blasko JC; Michalski J; Aronowitz J; Grimm P; Moran BJ; McLaughlin PW; Usher J; Lief JH; Allen ZA
Brachytherapy; 2005; 4(4):241-51. PubMed ID: 16344253
[TBL] [Abstract][Full Text] [Related]
20. Sequential comparison of seed loss and prostate dosimetry of stranded seeds with loose seeds in 125I permanent implant for low-risk prostate cancer.
Saibishkumar EP; Borg J; Yeung I; Cummins-Holder C; Landon A; Crook J
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):61-8. PubMed ID: 18823713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
